A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure - Scorecard - MDSpire

A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure

  • By

  • Himanshu Dhanda

  • Shamsuz Zaman

  • Bhavika Rishi

  • Raj Kamal

  • Manpreet Kaur

  • Nitika Anand

  • Baseer Noor

  • Pranay Tanwar

  • Sufian Zaheer

  • Prashant Prabhakar

  • Fouzia Siraj

  • Amitabh Singh

  • Aroonima Misra

  • May 21, 2026

  • 0 min

Share

Clinical Scorecard: A Preliminary Investigation into Asparaginase Therapeutic Drug Monitoring in High-Risk Pediatric ALL Patients in India: Findings Indicate Insufficient Drug Exposure

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationHigh-risk pediatric patients with B-cell ALL in India, aged 1-12 years, with specific mention of treatment protocols.
Care Setting

Key Highlights

  • Highlight the clinical implications of the observed toxicities.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider specifying alternative asparaginase preparations.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Detail the impact of suboptimal asparaginase exposure on treatment outcomes.

        Clinical Best Practices

        • Provide examples of population-specific pharmacokinetic parameters.

        Related Resources & Content

        Original Source(s)

        A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure

        • by Himanshu Dhanda, Shamsuz Zaman, Bhavika Rishi, Raj Kamal, Manpreet Kaur, Nitika Anand, Baseer Noor, Pranay Tanwar, Sufian Zaheer, Prashant Prabhakar, Fouzia Siraj, Amitabh Singh, Aroonima Misra

        • May 21, 2026

        Related Content

        Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

        Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

        Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

        • May 28, 2026